A few of America’s most respected corporations at the moment are leaning on OpenAI to meet main contracts, notes the FT.
Biotech Nephrogen combines AI and gene therapy to reverse kidney disease — check it out at TechCrunch Disrupt 2025
Oxford spinout RADiCAIT uses AI to make diagnostic imaging more affordable and accessible — catch it at TechCrunch Disrupt 2025
COI Energy solves a conundrum: Letting businesses sell unused electricity — catch it at TechCrunch Disrupt 2025